{"id":"https://openalex.org/W7204526330","doi":"https://doi.org/10.7759/cureus.115338","title":"Therapeutic Challenges in Metastatic Non-small Cell Lung Cancer (NSCLC) With Concurrent Mesenchymal-Epithelial Transition Factor (MET) Amplification and High Programmed Death-Ligand 1 (PD-L1) Expression: A Case Study","display_name":"Therapeutic Challenges in Metastatic Non-small Cell Lung Cancer (NSCLC) With Concurrent Mesenchymal-Epithelial Transition Factor (MET) Amplification and High Programmed Death-Ligand 1 (PD-L1) Expression: A Case Study","publication_year":2026,"publication_date":"2026-08-28","ids":{"openalex":"https://openalex.org/W7204526330","doi":"https://doi.org/10.7759/cureus.115338","pmid":"https://pubmed.ncbi.nlm.nih.gov/42802808"},"language":"en","primary_location":{"id":"doi:10.7759/cureus.115338","doi":"https://doi.org/10.7759/cureus.115338","is_oa":true,"landing_page_url":"https://doi.org/10.7759/cureus.115338","pdf_url":"https://www.cureus.com/articles/517092-therapeutic-challenges-in-metastatic-non-small-cell-lung-cancer-nsclc-with-concurrent-mesenchymal-epithelial-transition-factor-met-amplification-and-high-programmed-death-ligand-1-pd-l1-expression-a-case-study.pdf","source":{"id":"https://openalex.org/S2738950867","display_name":"Cureus","issn_l":"2168-8184","issn":["2168-8184"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310316779","host_organization_name":"Cureus, Inc.","host_organization_lineage":["https://openalex.org/P4310316779"],"host_organization_lineage_names":["Cureus, Inc."],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cureus","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.cureus.com/articles/517092-therapeutic-challenges-in-metastatic-non-small-cell-lung-cancer-nsclc-with-concurrent-mesenchymal-epithelial-transition-factor-met-amplification-and-high-programmed-death-ligand-1-pd-l1-expression-a-case-study.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5148551261","display_name":"Md. Arifur Rahman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Md. Arifur Rahman","raw_affiliation_strings":["Oncology and Radiotherapy, Bangladesh Specialized Hospital PLC, Dhaka, BGD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Radiotherapy, Bangladesh Specialized Hospital PLC, Dhaka, BGD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148544705","display_name":"Hasin Mesbah Bin Siddique","orcid":"https://orcid.org/0009-0008-7032-4314","observed_orcids":["https://orcid.org/0009-0008-7032-4314"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hasin Mesbah Bin Siddique","raw_affiliation_strings":["Oncology and Radiotherapy, Bangladesh Specialized Hospital PLC, Dhaka, BGD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Radiotherapy, Bangladesh Specialized Hospital PLC, Dhaka, BGD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148546622","display_name":"Mohammad S Faisal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mohammad S Faisal","raw_affiliation_strings":["Colorectal Surgery, Bangladesh Specialized Hospital PLC, Dhaka, BGD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Colorectal Surgery, Bangladesh Specialized Hospital PLC, Dhaka, BGD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148526413","display_name":"Masud Parvez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Masud Parvez","raw_affiliation_strings":["Pathology and Laboratory Medicine, Bangladesh Specialized Hospital PLC, Dhaka, BGD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pathology and Laboratory Medicine, Bangladesh Specialized Hospital PLC, Dhaka, BGD","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056167811","display_name":"Arman Reza Chowdhury","orcid":"https://orcid.org/0000-0002-3900-2914","observed_orcids":["https://orcid.org/0000-0002-3900-2914"]},"institutions":[{"id":"https://openalex.org/I4405254578","display_name":"Evercare Hospital Dhaka","ror":"https://ror.org/01zq65v31","country_code":"BD","type":"healthcare","lineage":["https://openalex.org/I4405254578"]}],"countries":["BD"],"is_corresponding":false,"raw_author_name":"Arman Reza Chowdhury","raw_affiliation_strings":["Oncology, Evercare Hospital Dhaka, Dhaka, BGD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Evercare Hospital Dhaka, Dhaka, BGD","institution_ids":["https://openalex.org/I4405254578"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.70644943,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"18","issue":"8","first_page":"e115338","last_page":"e115338"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12992","display_name":"Metastasis and carcinoma case studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-nsclc","display_name":"metastatic non-small cell lung cancer","score":0.9129999876022339},{"id":"https://openalex.org/keywords/met-amplification","display_name":"MET amplification","score":0.9160000085830688},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9490000009536743},{"id":"https://openalex.org/keywords/capmatinib","display_name":"capmatinib","score":0.9319999814033508},{"id":"https://openalex.org/keywords/met-inhibition","display_name":"MET inhibition","score":0.5040000081062317},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6439999938011169},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9850000143051147},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.4779999852180481},{"id":"https://openalex.org/keywords/tp53-mutation","display_name":"TP53 mutation","score":0.7310000061988831},{"id":"https://openalex.org/keywords/liver-dysfunction","display_name":"liver dysfunction","score":0.5440000295639038},{"id":"https://openalex.org/keywords/liver-failure","display_name":"liver failure","score":0.6589999794960022},{"id":"https://openalex.org/keywords/lung-adenocarcinoma","display_name":"lung adenocarcinoma","score":0.8169999718666077},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.5410000085830688},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.6890000104904175}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9553999900817871},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6171000003814697},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5669000148773193},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4244000017642975},{"id":"https://openalex.org/C194232998","wikidata":"https://www.wikidata.org/wiki/Q1606712","display_name":"Transition (genetics)","level":3,"score":0.3711000084877014},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3328000009059906},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32499998807907104},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.29330000281333923},{"id":"https://openalex.org/C76419328","wikidata":"https://www.wikidata.org/wiki/Q74419","display_name":"Epithelial\u2013mesenchymal transition","level":4,"score":0.2786000072956085},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.26350000500679016}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.7759/cureus.115338","doi":"https://doi.org/10.7759/cureus.115338","is_oa":true,"landing_page_url":"https://doi.org/10.7759/cureus.115338","pdf_url":"https://www.cureus.com/articles/517092-therapeutic-challenges-in-metastatic-non-small-cell-lung-cancer-nsclc-with-concurrent-mesenchymal-epithelial-transition-factor-met-amplification-and-high-programmed-death-ligand-1-pd-l1-expression-a-case-study.pdf","source":{"id":"https://openalex.org/S2738950867","display_name":"Cureus","issn_l":"2168-8184","issn":["2168-8184"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310316779","host_organization_name":"Cureus, Inc.","host_organization_lineage":["https://openalex.org/P4310316779"],"host_organization_lineage_names":["Cureus, Inc."],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cureus","raw_type":"journal-article"},{"id":"pmid:42802808","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42802808","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cureus","raw_type":"Case Reports"},{"id":"pmh:oai:pubmedcentral.nih.gov:13616099","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13616099/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Cureus","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.7759/cureus.115338","doi":"https://doi.org/10.7759/cureus.115338","is_oa":true,"landing_page_url":"https://doi.org/10.7759/cureus.115338","pdf_url":"https://www.cureus.com/articles/517092-therapeutic-challenges-in-metastatic-non-small-cell-lung-cancer-nsclc-with-concurrent-mesenchymal-epithelial-transition-factor-met-amplification-and-high-programmed-death-ligand-1-pd-l1-expression-a-case-study.pdf","source":{"id":"https://openalex.org/S2738950867","display_name":"Cureus","issn_l":"2168-8184","issn":["2168-8184"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310316779","host_organization_name":"Cureus, Inc.","host_organization_lineage":["https://openalex.org/P4310316779"],"host_organization_lineage_names":["Cureus, Inc."],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cureus","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.7532907128334045,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7204526330.pdf","grobid_xml":"https://content.openalex.org/works/W7204526330.grobid-xml"},"referenced_works_count":20,"referenced_works":["https://openalex.org/W2785972324","https://openalex.org/W2889307896","https://openalex.org/W2922104964","https://openalex.org/W2952892955","https://openalex.org/W3033982788","https://openalex.org/W3082015854","https://openalex.org/W3113250245","https://openalex.org/W3130149655","https://openalex.org/W3133838590","https://openalex.org/W3175481001","https://openalex.org/W3196585382","https://openalex.org/W3214844045","https://openalex.org/W4295067656","https://openalex.org/W4296642233","https://openalex.org/W4375950476","https://openalex.org/W4389688259","https://openalex.org/W4390745276","https://openalex.org/W4391787162","https://openalex.org/W4406587284","https://openalex.org/W7160037612"],"related_works":[],"abstract_inverted_index":{"Mesenchymal-epithelial":[0],"transition":[1],"factor":[2],"(MET)":[3],"amplification":[4,92,248],"is":[5],"an":[6,98,262],"uncommon":[7],"but":[8],"important":[9],"oncogenic":[10],"driver":[11],"in":[12,65],"non-small":[13],"cell":[14,123],"lung":[15,84],"cancer":[16],"(NSCLC),":[17],"and":[18,38,58,70,74,104,118,140,159,198,223,225,236,249,282,299],"its":[19],"coexistence":[20],"with":[21,49,53,62,155,272,306],"high":[22,105,250],"programmed":[23],"death-ligand":[24],"1":[25],"(PD-L1)":[26],"expression":[27,107,252],"creates":[28],"a":[29,44,101,119,156,160,169,184,191,209,255,285,292],"therapeutic":[30],"dilemma":[31],"over":[32],"how":[33],"to":[34,258],"sequence":[35],"MET-directed":[36],"therapy":[37,245],"immune":[39],"checkpoint":[40],"inhibition.":[41],"We":[42],"report":[43],"65-year-old":[45],"man":[46],"who":[47],"presented":[48],"weight":[50],"loss,":[51],"hoarseness":[52],"left":[54],"vocal":[55],"cord":[56],"palsy,":[57],"right":[59],"supraclavicular":[60],"lymphadenopathy,":[61],"metastatic":[63,83],"disease":[64],"the":[66,130,138,181,241,268],"lungs,":[67],"lymph":[68],"nodes,":[69],"bone":[71],"(with":[72],"hepatic":[73,162,205],"brain":[75,174,196],"metastasis":[76],"emerging":[77],"later":[78],"on":[79],"therapy).":[80],"Biopsy":[81],"confirmed":[82],"adenocarcinoma.":[85],"Comprehensive":[86],"genomic":[87],"profiling":[88],"(CGP)":[89],"showed":[90],"MET":[91,185,247,264,280],"(copy":[93],"number":[94,266],"gain":[95],"of":[96,126,183,211,217,243],"8,":[97],"intermediate-level":[99],"amplification),":[100],"TP53":[102],"mutation,":[103,189],"PD-L1":[106,141,251,301],"(tumor":[108],"proportion":[109],"score":[110,125],"(TPS)":[111],"~80%":[112],"by":[113,173,295],"22C3":[114],"immunohistochemistry":[115],"at":[116,128],"diagnosis":[117,232],"VENTANA":[120],"SP142":[121],"tumor":[122],"(TC)":[124],"90%":[127],"progression;":[129],"two":[131],"assays":[132],"are":[133],"not":[134],"directly":[135],"comparable).":[136],"Because":[137],"CGP":[139],"results":[142,302],"returned":[143],"only":[144],"after":[145,231],"treatment":[146],"had":[147],"started,":[148],"first-line":[149],"platinum-doublet":[150],"chemotherapy":[151],"(nab-paclitaxel/carboplatin)":[152],"was":[153,216,221],"given,":[154],"mixed":[157],"response":[158,194,257],"new":[161],"metastasis.":[163],"Second-line":[164],"atezolizumab":[165],"plus":[166],"pemetrexed/carboplatin":[167],"produced":[168,190],"partial":[170],"response,":[171],"followed":[172],"metastases.":[175],"Third-line":[176],"off-label":[177],"capmatinib,":[178],"used":[179],"despite":[180,261],"absence":[182],"exon":[186],"14":[187],"skipping":[188],"marked":[192,256],"systemic":[193],"following":[195],"radiotherapy":[197],"subsequent":[199],"capmatinib.":[200],"The":[201],"patient":[202],"then":[203],"developed":[204],"dysfunction":[206],"that,":[207],"against":[208],"background":[210],"concurrent":[212],"radiological":[213],"liver":[214,234],"progression,":[215],"uncertain":[218],"cause;":[219],"capmatinib":[220,259],"reduced":[222],"stopped,":[224],"he":[226],"died":[227],"approximately":[228],"30":[229],"months":[230],"from":[233],"failure":[235],"sepsis.":[237],"This":[238],"case":[239],"illustrates":[240],"difficulty":[242],"sequencing":[244],"when":[246],"coexist.":[253],"Notably,":[254],"occurred":[260],"intermediate":[263],"copy":[265],"below":[267],"threshold":[269],"usually":[270],"associated":[271],"benefit.":[273],"Any":[274],"role":[275],"for":[276],"combined":[277],"or":[278],"sequential":[279],"inhibition":[281],"immunotherapy":[283],"remains":[284],"hypothesis":[286],"requiring":[287],"prospective":[288],"study":[289],"rather":[290],"than":[291],"conclusion":[293],"supported":[294],"this":[296],"single":[297],"case,":[298],"cross-assay":[300],"should":[303],"be":[304],"interpreted":[305],"caution.":[307]},"counts_by_year":[],"updated_date":"2026-09-30T09:27:27.532063","created_date":"2026-08-29T00:00:00"}